Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Celularity (CELU) over the last 6 years, with Q3 2025 value amounting to $822000.0.

  • Celularity's Change in Accured Expenses fell 7984.31% to $822000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 23116.26%. This contributed to the annual value of $12.6 million for FY2024, which is 122003.55% up from last year.
  • As of Q3 2025, Celularity's Change in Accured Expenses stood at $822000.0, which was down 7984.31% from $6.2 million recorded in Q2 2025.
  • Celularity's 5-year Change in Accured Expenses high stood at $6.2 million for Q2 2025, and its period low was -$9.2 million during Q4 2022.
  • Its 5-year average for Change in Accured Expenses is $886263.2, with a median of $888000.0 in 2023.
  • Examining YoY changes over the last 5 years, Celularity's Change in Accured Expenses showed a top increase of 1376595.55% in 2021 and a maximum decrease of 78575.07% in 2021.
  • Celularity's Change in Accured Expenses (Quarter) stood at -$5.6 million in 2021, then tumbled by 62.37% to -$9.2 million in 2022, then soared by 70.98% to -$2.7 million in 2023, then soared by 302.82% to $5.4 million in 2024, then crashed by 84.77% to $822000.0 in 2025.
  • Its Change in Accured Expenses was $822000.0 in Q3 2025, compared to $6.2 million in Q2 2025 and $2.7 million in Q1 2025.